Overcoming Cancers Resistant to Her 2 Antibodies

Produk Detail:
  • Author : Benjamin Bonavida
  • Publisher : Sensitizing Agents for Cancer
  • Pages : 250 pages
  • ISBN : 9780128164082
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Overcoming Cancers Resistant to Her 2 Antibodies

Download or Read online Overcoming Cancers Resistant to Her 2 Antibodies full in PDF, ePub and kindle. this book written by Benjamin Bonavida and published by Sensitizing Agents for Cancer which was released on 15 December 2019 with total page 250 pages. We cannot guarantee that Overcoming Cancers Resistant to Her 2 Antibodies book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Therefore, the use of various immunosensitizing agents to reverse resistance has been considered and this book discusses each of them in depth, such as Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Overcoming Cancers Resistant to Her 2 Antibodies

Overcoming Cancers Resistant to Her 2 Antibodies
  • Author : Benjamin Bonavida
  • Publisher : Sensitizing Agents for Cancer
  • Release : 15 December 2019
GET THIS BOOK Overcoming Cancers Resistant to Her 2 Antibodies

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher : Springer
  • Release : 15 July 2019
GET THIS BOOK Current Applications for Overcoming Resistance to Targeted Therapies

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer
  • Author : Benjamin Bonavida
  • Publisher : Springer Science & Business Media
  • Release : 04 August 2013
GET THIS BOOK Resistance to Immunotherapeutic Antibodies in Cancer

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can

Cancer Chemotherapy and Biotherapy

Cancer Chemotherapy and Biotherapy
  • Author : Bruce A. Chabner,Dan L. Longo
  • Publisher : Lippincott Williams & Wilkins
  • Release : 07 December 2011
GET THIS BOOK Cancer Chemotherapy and Biotherapy

Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab
  • Author : Banujan Balachandran
  • Publisher : Unknown
  • Release : 09 December 2021
GET THIS BOOK Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

"Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab, a humanized monoclonal antibody binding to the extracellular domain of HER-2, has proven to be a beneficial treatment for patients diagnosed as HER-2+ but continues to have limitations. With low response rates for patients when administered alone and for patients having received prior chemotherapy, the true potential of trastuzumab seems to arrive only through combination

PDK 1 Akt Pathway as Targets for Chemosensitizing Effects

PDK 1 Akt Pathway as Targets for Chemosensitizing Effects
  • Author : Ping-Hui Tseng
  • Publisher : Unknown
  • Release : 09 December 2021
GET THIS BOOK PDK 1 Akt Pathway as Targets for Chemosensitizing Effects

Abstract: Cancer is the leading causes of human deaths all over the world. The growing understanding in cancer biology provides the researchers to develop molecularly targeted therapeutic strategies. However, the toxicity and resistance limit the applications for molecularly targeted agents. Here, we proposed that inhibiting PI3K/PDK-1/Akt signaling pathway, which is critical in controlling cell survival and proliferation, is able to enhance the therapeutic effects and overcome resistance of the current used molecularly targeted drugs. Imatinib (STI571; Gleevec),

Translational Research in Breast Cancer

Translational Research in Breast Cancer
  • Author : Dong-Young Noh,Erwei Song,Hai Hu,Wonshik Han,Masakazu Toi
  • Publisher : Springer Nature
  • Release : 09 December 2021
GET THIS BOOK Translational Research in Breast Cancer

This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in

Monoclonal Antibodies Advances in Research and Application 2012 Edition

Monoclonal Antibodies   Advances in Research and Application  2012 Edition
  • Author : Anonim
  • Publisher : ScholarlyEditions
  • Release : 26 December 2012
GET THIS BOOK Monoclonal Antibodies Advances in Research and Application 2012 Edition

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Monoclonal Antibodies. The editors have built Monoclonal Antibodies—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Monoclonal Antibodies in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Monoclonal Antibodies—Advances in Research and

Cancer Cell Signaling

Cancer Cell Signaling
  • Author : Kasirajan Ayyanathan
  • Publisher : CRC Press
  • Release : 20 June 2014
GET THIS BOOK Cancer Cell Signaling

This title includes a number of Open Access chapters. Cell signaling is a field that studies how cells communicate to control basic activities and respond to their environment. When looking specifically at cancer cells, researchers can gain a better understanding of cancer on a cellular level, an understanding that may have implications for developing new treatments. The current volume provides an overview of the field and how various cell biology techniques are used to better understand cancer on a cellular

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
  • Author : Goli Samimi,Christina Annunziata
  • Publisher : Academic Press
  • Release : 06 November 2020
GET THIS BOOK Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment.

Translational Medicine

Translational Medicine
  • Author : Robert A. Meyers
  • Publisher : John Wiley & Sons
  • Release : 29 April 2016
GET THIS BOOK Translational Medicine

The first complete overview of progress in the field. The two volumes contain selected articles from the prestigious online Encyclopedia of Molecular Cell Biology and Molecular Medicine, fully updated and enriched with numerous new contributions from many eminent scientists. Divided into three parts, the first gives a thorough introduction to cancer biology, while Part Two covers therapeutic approaches for all major forms of cancer, and the third part deals with cancer diagnostics. The result is a one-stop resource for advanced

Handbook of HER2 targeted agents in breast cancer

Handbook of HER2 targeted agents in breast cancer
  • Author : Ricardo H Alvarez,Javier Cortés,Leticia Mattos-Arruda,Mary Falzon,Angelica Fasolo,Michael Gandy,Luca Gianni,Nadia Harbeck,Martine Piccart,Stefania Zambelli,Dimitrios Zardavas
  • Publisher : Springer
  • Release : 28 May 2014
GET THIS BOOK Handbook of HER2 targeted agents in breast cancer

​Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook

Resistance to Targeted Therapies in Breast Cancer

Resistance to Targeted Therapies in Breast Cancer
  • Author : Jenifer R. Prosperi
  • Publisher : Springer
  • Release : 04 December 2017
GET THIS BOOK Resistance to Targeted Therapies in Breast Cancer

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into

Breast Cancer

Breast Cancer
  • Author : Mehmet Gunduz,Esra Gunduz
  • Publisher : BoD – Books on Demand
  • Release : 30 November 2011
GET THIS BOOK Breast Cancer

Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as